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The past decade has witnessed a number of exciting developments in the ﬁeld of mitochondrial dy-
namics – a phenomenon in which changes in mitochondrial shape and movement impact on cellular
physiology and pathology. By undergoing fusion and ﬁssion, mitochondria are able to change their
morphology between elongated interconnected networks and discrete fragmented structures, respec-
tively. The cardiac mitochondria, in particular, have garnered much interest due to their unique spatial
arrangement in the adult cardiomyocyte, and the multiple roles they play in cell death and survival. In
this article, we review the role of the mitochondrial fusion and ﬁssion proteins as novel therapeutic
targets for treating cardiovascular disease.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
In the heart, the mitochondria occupy nearly one third the volume
of a cardiomyocyte – they sustain the energy required for normal
cardiac contractile function by producing up to 30 kg of adenosine
triphosphate (ATP) per day. However, the role of cardiac mitochondria
extends far beyond that of being merely the ‘powerhouse’ of the cell.
The past decade has witnessed a number of developments in the ﬁeld
of mitochondrial dynamics – a phenomenon in which changes in
mitochondrial shape and movement have been demonstrated to im-
pact on cellular physiology and pathology. Mitochondria are dynamic
organelles which are able to change their shape by undergoing fusion
to generate elongated interconnected mitochondrial networks, andr B.V. This is an open access article
olic Diseases Program, Duke-
apore 169857, Singapore.
(D.J. Hausenloy).ﬁssion to produce discrete fragmented mitochondria. These processes
are under the regulation of the mitochondrial fusion and ﬁssion pro-
teins, respectively, and are essential for maintaining a healthy mi-
tochondrial network. The cardiac mitochondria, in particular, have
garnered much interest due to their unique spatial arrangement in the
adult heart, and the multiple roles they play in cell death and survival.
It is known that the actions of the mitochondrial fusion and ﬁssion
proteins extend beyond those of mediating changes in mitochondrial
shape – in this regard these pleiotropic roles may impact on their
effects in the heart and the vasculature (see Fig. 1). In this article, we
review the potential role for the mitochondrial fusion and ﬁssion
proteins as novel targets for treating cardiovascular disease.
2. Mitochondrial fusion
The fusion of two adjacent mitochondria allows the mixing of
intra-mitochondrial proteins and the replacement of damagedunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. This scheme provides an overview of the role of the mitochondrial fusion and ﬁssion proteins as potential therapeutic targets for treating cardiovascular disease.
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outer mitochondrial membrane (OMM), Mitofusins 1 (MFN1)
and 2 (MFN2) mediate the fusion of the OMM, whereas in the
inner mitochondrial membrane (IMM), Optic Atrophy 1 (OPA1),
governs the fusion of the IMM (reviewed in Youle and
van der Bliek (2012)). The mitochondrial fusion proteins contain a
GTPase domain, a transmembrane domain, and a coiled-coil
domain. The proteins are anchored to the mitochondrial
membrane by the transmembrane domain and it is the coiled-coil
domains facing the cytosol that mediate the formation
of homotypic (MFN1–MFN1, MFN2–MFN2 and OPA1–OPA1) or
heterotypic (MFN1–MFN2) physical connections (Chen et al.,
2003). These links bring adjacent mitochondria together and
initiate the fusion of the OMM (Koshiba et al., 2004; Chan, 2006),
while the formation of OPA1–OPA1 homotypic complexes fuse
the IMM.
2.1. The Mitofusins (MFN1 and MFN2)
The main role of the Mitofusins is to mediate the fusion of the
OMM of adjacent mitochondria. The GTPase activity of the Mito-
fusins is regulated by guanine nucleotide binding protein-β sub-
unit 2 (Gβ2) (Zhang et al., 2010), and in this regard, MFN1 has been
reported to have a higher GTPase activity as compared to that of
MFN2 (Ishihara et al., 2004). The pro-fusion effects of MFN1 can be
promoted by binding of Gβ2 to MFN1 which decreases its motility
and facilitates its clustering at speciﬁc foci on the OMM (Zhang
et al., 2010). MFN2, however, is regulated by expression levels
rather than other post-translational modiﬁcations. One such sce-
nario is during mitochondrial biogenesis where PGC1-α and PGC1-
β up-regulate MFN2 expression to promote mitochondrial fusion
(Zorzano et al., 2009; Liesa et al., 2008). Nevertheless, the ubi-
quitination of MFN1 and MFN2 promotes the degradation of these
proteins allowing unopposed mitochondrial ﬁssion during the
selective removal of dysfunctional mitochondria by mitophagy
(Tanaka et al., 2010; Gegg et al., 2010).
2.1.1. Pleiotropic non-fusion roles of Mitofusins
The role of the Mitofusins extends beyond that of mediating
mitochondrial fusion of the OMM – this makes the investigation of
these proteins in the adult heart quite challenging. Pleiotropic
non-fusion actions of the Mitofusins have been mainly describedfor MFN2 although emerging studies suggest that MFN1 may also
have non-fusion effects.
2.1.1.1. MFN2 as a tethering protein. MFN2 has been shown to te-
ther the endoplasmic reticulum (ER) to mitochondria thereby al-
lowing the formation of subcellular calcium (Ca2þ) domains in
close proximity to the mitochondrial calcium uniporter, and fa-
cilitating the transfer of Ca2þsignalling from the ER to mitochon-
dria (De Brito and Scorrano, 2008). In the heart, efﬁcient Ca2þ
transfer from the sarcoplasmic reticulum (SR) to mitochondria is
essential to tightly couple the energy requirements for cardiac
contractility to mitochondrial energy production (Y. Chen et al.,
2012). It has been demonstrated that in mice lacking cardiac-
speciﬁc MFN2, the SR-mitochondrial tethering is disrupted re-
sulting in impaired Ca2þ signalling, diminished mitochondrial
respiratory function and a deterioration in left ventricular (LV)
systolic function.
2.1.1.2. MFN2 and apoptotic cell death. The interactions between
pro-apoptotic proteins such as BAX and BAK which translocate to
and permeate the OMM, and the mitochondrial fusion and ﬁssion
proteins remain to be fully elucidated (Youle and Strasser, 2008).
Both BAX and BAK have been demonstrated to co-localise with
MFN2 in the OMM (Karbowski et al., 2002; Neuspiel et al., 2005).
The binding of BAX to MFN2 has been shown to inhibit its pro-
fusion function (Neuspiel et al., 2005). MFN2 may also promote
mitochondrial pore formation and decrease stability of the mi-
tochondrial membrane thereby facilitating Drp1-mediated mi-
tochondrial ﬁssion (Papanicolaou, Phillippo, et al., 2012). The po-
tential role of non-oligomerised or monomeric BAX and BAK in
mitochondrial fusion has recently been evaluated in the context of
mitochondrial permeability transition pore (MPTP) opening and
necrotic cell death (Whelan et al., 2012). Combined ablation of
BAX and BAK was found to promote mitochondrial fragmentation,
yet the mitochondria were still shown to be resistant to MPTP
opening and necrotic cell death. Interestingly, MFN2-deﬁcient cells
(Whelan et al., 2012) also exhibited resistance against MPTP
opening, supporting the observation that MFN2 may promote this
process together with BAX. This notion is based on the speculation
that BAX localisation to the OMM may facilitate the formation of
hemifusion-related holes which can be used in the exchange of
ions during MPTP opening in the presence of stress. The
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synthase) relative to the F1F0-ATP synthase prevents cell death
mediated by release of cytochrome c (cytc), elevated release of ER
[Ca2þ], recruitment of Drp1 and BAX insertion into the OMM
(Faccenda et al., 2013). There appears to be signiﬁcant crosstalk
between apoptosis and necrosis based on the ﬁnding that cells and
mitochondria lacking BAX and BAK are resistant to MPTP opening
and necrosis, suggesting that BAX and BAK play distinct roles in
regulating both apoptosis and necrosis (Whelan et al., 2012). This
was further shown where BAX/BAK/cyclophilin D triple knockout
mice did not appear to exhibit a further reduction in myocardial
infarct size when compared to the BAX/BAK double knockout mice
(Whelan et al., 2012). In addition, the positioning of the BH3-only
proteins may also dictate whether apoptosis or necrosis ensues
(Diwan et al., 2009; Chen et al., 2010).
2.1.1.3. MFN2 as a mediator of mitophagy. Cardiac-speciﬁc deletion
of MFN2 has been reported to impair cellular autophagy as evi-
denced by the accumulation of autophagosomes (Zhao et al., 2012).
The actual mechanism underlying the role of MFN2 in the autophagic
response was not elucidated, although MFN2 was shown to associate
with RAB7, an autophagosome maturation-related protein (Zhao
et al., 2012). A recent study has delineated the role of MFN2 in mi-
tophagy. Damaged mitochondria lose their mitochondrial membrane
potential which then induces the translocation of PINK1 to the OMM
(Leboucher et al., 2012), where it phosphorylates MFN2 at Thr-111
and Ser-442, thereby allowing the binding of Parkin, which then
ubiquitinates MFN2 (Chen and Dorn, 2013). The ubiquitination of
MFN2 inhibits its pro-fusion activity allowing mitochondrial ﬁssion,
while recruiting p62 to facilitate selective removal of the damaged
mitochondrion by mitophagy (Chen and Dorn, 2013; Gegg et al.,
2010; Tanaka et al., 2010; Glauser et al., 2011).
2.2. OPA1
The IMM fusion protein, OPA1, mediates fusion of the IMM of two
adjacent mitochondria. OPA1 function is determined by alternative
splicing and post-translational modiﬁcation, making its regulation
somewhat complex, and only a simpliﬁed overview is presented here
(for a more detailed review please see Burke et al. (2015)).
2.2.1. Pleiotropic non-fusion roles of OPA1
The IMM mitochondrial fusion protein, OPA1, has been re-
ported to display a number of non-fusion roles which have been
shown to impact on cristae morphology and mitochondrial re-
spiratory efﬁciency.
2.2.1.1. OPA1 and mitophagy. A recent study by Sadoshima's group
has demonstrated that Drp1 down-regulation elongates the mi-
tochondria but inhibits mitophagy and causes mitochondrial
dysfunction, thereby promoting LV dysfunction and increased
susceptibility to I/R injury (Ikeda et al., 2015). Under conditions of
stress, Parkin is recruited to the linear ubiquitin assembly complex
and increases linear ubiquitination of NF-κB essential modulator
(NEMO), which is essential for canonical NF-κB signalling. The NF-
κB-responsive promoter elements then signals for up-regulation of
OPA1 to maintain mitochondrial integrity and protect from cell
death. The lack of mitophagy, however, did not hamper the Parkin-
induced protection (Müller-Rischart et al., 2013).
2.2.1.2. Cristae remodelling and mitochondrial apoptosis. By reg-
ulating mitochondrial cristae morphology, cytc distribution, and
apoptotic cell death, OPA1 has been shown to exert a strong anti-
apoptotic effect. It is well-established that cristae remodelling
(cristae fusion and widening of the cristae junction) by tBID is
required for the redistribution of cytc from the intra-cristal spaceinto the intermembrane space (IMS) and the initiation of apoptosis
(Scorrano et al., 2002; Kim et al., 2004; Frezza et al., 2006; Epand
et al., 2002). By ‘stapling’ these cristae junctions closed, OPA1 has
been shown to prevent the redistribution of cytochrome c, thereby
preventing cytochrome c release and inhibiting apoptotic cell
death (Frezza et al., 2006). These ﬁndings implicate OPA1 as a
critical regulator of apoptotic cell death and therefore a ther-
apeutic target for protecting against apoptosis.
2.2.1.3. Cristae remodelling and mitochondrial respiratory efﬁ-
ciency. The respiratory complexes of the electron transport chain
(ETC) are assembled into respiratory chain supercomplexes (RCS),
the arrangement of which facilitates the transfer of electrons be-
tween the respiratory complexes, thereby improving mitochon-
drial respiratory efﬁciency (reviewed in Saraste (1999) and Schäfer
et al. (2006)). The regulation of cristae morphology by OPA1 has
been recently shown to impact on the formation of RCS and mi-
tochondrial energy production. Using genetic manipulation of
OPA1, Cogliati et al. (2013) have demonstrated that the stability
and assembly of RCS, mitochondrial respiratory efﬁciency, and
mitochondria-dependent cell growth were critically dependent on
cristae morphology. These ﬁndings implicate OPA1 as a critical
regulator of mitochondrial respiration and therefore a therapeutic
target for modulating mitochondrial energy production.3. Mitochondrial ﬁssion
Mitochondrial ﬁssion ensures equal division of mitochondrial
numbers during cell division and mediates the selective removal of
damaged mitochondria by the process of mitophagy. The process of
mitochondrial ﬁssion is mediated by Drp1 which translocates from
the cytosol to the OMM where it interacts with other proteins of the
ﬁssion machinery including human ﬁssion protein-1 (hFis1), mi-
tochondrial ﬁssion factor (Mff), and mitochondrial dynamics proteins
of 49 (MiD49) and 51 kDa (MiD51), although the actual interplay
between these proteins remains unclear (reviewed in Otera et al.
(2013) and Elgass et al. (2013)). At the OMM, Drp1 then oligomerises
forming a spiral which encircles the mitochondrion and mediates the
scission of the latter. It appears that Drp-1 mediated mitochondrial
ﬁssion is initiated by early constriction of mitochondria after making
contact with the endoplasmic reticulum (ER) (Friedman et al., 2011),
through the association of the ER-associated inverted formin 2 (INF2,
a formin that accelerates both actin polymerisation and depolymer-
isation) and the actin component of the cytoskeleton (Korobova et al.,
2013; De Vos et al., 2005). It has been suggested that the ER encircles
mitochondria at sites of ﬁssion, and ER-associated INF2 then stimu-
lates actin polymerisation, providing the force required for partial
constriction of the mitochondria, thereby facilitating the transloca-
tion of Drp1 to these pre-constriction contact sites in the OMM. The
actual mechanism through which Drp1 localises to these pre-con-
stricted ER-contact sites on the OMM, and the roles which hFis1, Mff
and MiD49/51 play in this process remains to be determined.
The translocation of Drp1 from the cytosol to the mitochondria
is regulated by a number of different post-translational modiﬁca-
tions including SUMOylation (Figueroa-Romero et al., 2009),
phosphorylation (Cribbs and Strack, 2007; Cho et al., 2010; Chang
and Blackstone, 2007), ubiquitination (Nakamura et al., 2006),
S-nitrosylation (D.-H. Cho et al., 2009), and O-GlcNAcylation
(Gawlowski et al., 2012). The phosphorylation of Ser-637 by pro-
tein kinase A (PKA) (Cribbs and Strack, 2007; Chang and Black-
stone, 2007), Ca2þ/calmodulin-dependent protein kinase (CaM
Kinase) (Han et al., 2008), and Proto-oncogene serine/threonine-
protein kinase Pim-1 (Pim1) (Din et al., 2013) has been shown to
prevent the mitochondrial translocation of Drp1. In contrast, the
phosphorylation of Ser-616 by Cdk1/cyclin B (a key mitotic kinase)
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(Taguchi et al., 2007; Marsboom et al., 2012). Under conditions of
high cytosolic Ca2þ , dephosphorylation of Drp1 at Ser-637 by
calcineurin induces mitochondrial ﬁssion (Cribbs and Strack, 2007;
Cereghetti et al., 2008; Cho et al., 2010; Sandebring et al., 2009;
Estaquier and Arnoult, 2007). In hyperglycaemic conditions,
O-GlcNAcylation of OPA1 (Makino et al., 2011) and Drp1 (Gaw-
lowski et al., 2012) causes dephosphorylation of Ser-637 and the
translocation of Drp1 to the OMM.
3.1. Drp1 and cell death
In addition to co-localisation with BAX at the OMM, Drp1 has
also been reported to be recruited by BAX in response to apoptotic
stimuli (Karbowski et al., 2002) and stabilised by SUMO-mediated
ubiquitination (Wasiak et al., 2007). Drp1 promotes mitochondrial
fragmentation, loss of MMP and release of cytc when localised to
the OMM. Nevertheless, Drp1 inhibition only slows down rather
than fully inhibits apoptosis as other pro-apoptotic proteins may
still be released from the mitochondria (Estaquier and Arnoult,
2007; Frank et al., 2001). Furthermore, there is growing evidence
that apoptosis can still occur regardless of the fragmentation of the
mitochondria (Parone et al., 2006; Wakabayashi et al., 2009).
In contrast to the previously held belief that necrosis is un-
regulated, a pathway of programmed cell necrosis has been re-
cently described.The cytokine TNF-α activates the receptor-inter-
acting serine–threonine kinases RIP1 and RIP3 which interact with
the mixed lineage kinase domain like protein (MLKL) resulting in
ROS generation, Ca2þoverload, and the opening of the MPTP
(Vanlangenakker et al., 2008; Y.S. Cho et al., 2009; Chen et al.,
2013). RIP3 forms a complex with the mitochondrial protein
phosphatase PGAM5, which recruits Drp1 to the OMM by de-
phosphorylating its Ser-637 site to cause mitochondrial fragmen-
tation (Wang et al., 2012), although Drp1 was deemed to be un-
necessary in necroptosis induced by RIPK3 in more recent ﬁndings
(Moujalled et al., 2014; Remijsen et al., 2014). These ﬁndings im-
plicate a role for Drp1 in mediating programmed cell death ne-
crosis. Caspase-8 also suppresses the RIP3–RIP1 kinase complex-
dependent necroptosis by proteolytic cleavage (He et al., 2009).
Caspase-8 deﬁcient embryos die between embryonic days 10.5
and 11.5 due to the activation of RIP3 (He et al., 2009). Double KO
of RIP3 and caspase-8 avoided mortality and allowed for matura-
tion into adult (Kaiser et al., 2011). Pharmacological inhibition of
this pathway, using Necrostatin-1 to target RIP1, has been reported
to limit MI size and prevent post-LV remodelling in cell lines as
well as animal models of acute IRI (Oerlemans et al., 2012; Lim
et al., 2007; L. Zhang et al., 2013). Repression of RIP3 or MLKL
blocks necroptosis but activates RIP1-dependent apoptosis al-
though the possibility of this being due to different species was
raised (Remijsen et al., 2014). In addition, the different identities of
cell death initiators may dictate the pathway of necroptosis
(Obitsu et al., 2013). The signalling events underlying necroptosis
have been shown to involve Akt/mTOR as well in the neuron
model where cell death was preceded by RIPK1-RIPK3-pAkt as-
sembly (Liu et al., 2014).4. Mitochondrial fusion and ﬁssion proteins and the adult
heart
In the adult heart where the unique spatial arrangement of
mitochondria restricts their mobility and distributes them into
3 distinct subpopulations (subsarcolemmal, interﬁbrillar, and
perinuclear), the relevance of mitochondrial dynamics is not easily
apparent. Although relatively immobile, experimental studies have
demonstrated that cardiac mitochondria do form aninterconnected network, and both fusion and ﬁssion events do
occur thus allowing for the exchange of mitochondrial contents
and the selective removal of damaged mitochondria within the
cardiomyocyte, albeit at a much slower rate. By tracking the
movement of photo-activatable green ﬂuorescentprotein (PAGFP)
across the cardiomyocyte over several hours, Huang et al. (2013)
were able to demonstrate that cardiac mitochondria formed an
interconnected network which allowed for the exchange of mi-
tochondrial content.
4.1. Cardiac development and maturation
Genetic ablation of both MFN1 and MFN2 causes death in utero
during the mid-gestation period (Chen et al., 2003) whereas car-
diac-speciﬁc ablation of both Mitofusins in the embryo was shown
to be lethal at day E9.5–10.5 (Chen et al., 2011). Together, these
ﬁndings imply a role for the Mitofusins in cardiac development.
The complete ablation of OPA1 causes in utero death, thus un-
derscoring the importance of this protein in embryonic develop-
ment and maintenance of mitochondrial integrity (Davies et al.,
2007). Finally, the Drp1 knockout mouse is embryonically lethal at
day E12.5 conﬁrming an essential role for this mitochondrial ﬁs-
sion protein in embryonic development (Manczak et al., 2012).
In the ﬁrst few days of post-natal growth, major changes in
cardiac metabolism and intracellular architecture occur – these are
required to support the increased energy required for cardiac
growth and maturation. In order to support a change in mi-
tochondrial respiration from glycolysis to oxidative phosphoryla-
tion, there is a shift in mitochondrial morphology from a frag-
mented phenotype to elongated mitochondria aligned with the
myoﬁbrils. This change in mitochondrial morphology is reliant on
the increased levels of Mitofusins present at this time (Papanico-
laou, Kikuchi, et al., 2012). Furthermore, transgenic mice (loxP/
Myh6-Cre) deﬁcient in cardiac-speciﬁc MFN1 and MFN2 from the
late embryonic period displayed severe mitochondrial dysfunction
at 7 days (abnormal mitochondrial structure, down-regulated
mitochondrial biogenesis genes, reduced mitochondrial DNA),
developed cardiomyopathy, and all died before 14 days old (Pa-
panicolaou, Kikuchi, et al., 2012). The shift towards a more elon-
gated phenotype also depends on a reduction in cardiac hypoxia-
inducible factor (HIF) signalling, which mediates an increase in
fusion protein expression from E16.5 in a stepwise manner
through to P10.5 with the largest increase taking place between
P0.5 and P2.5 in MFN1 and MFN2 and between P2.5 and P10.5 in
OPA1 while no changes were detectable in ﬁssion protein Drp1
and Fis1 levels over this time period (Neary et al., 2014). Postnatal
growth of the heart also witnesses a role for PGC-lα in stimulating
the transcription of MFN1 gene by co-activating the orphan nu-
clear receptor ERRα. Nonetheless, PGC-1 co-activators are dis-
pensable for maintenance of mitochondria in the adult heart, but
required for a high-level expression of nuclear- and mitochon-
drial-encoded genes involved in mitochondrial energy transduc-
tion and OXPHOS pathways, and for full respiratory capacity
(Martin et al., 2014).
Another critical change which occurs at the time of birth is
closure of the ductus arteriosus (DA) in response to the increase in
oxygen thereby diverting blood from the right ventricle into the
pulmonary circulation. Failure of the DA to close can result in
pulmonary congestion and failure to thrive. The presence of oxy-
gen in this setting rapidly induces phosphorylation of Drp1 at Ser-
616 in less than 5 min to promote fragmentation of mitochondria
in DA smooth muscle cells. The fragmentation of mitochondria
induced production of signalling ROS which activated closure of
the DA via inhibition of oxygen-sensitive potassium channels.
L-type channel activation increased intracellular calcium and
subsequent vasoconstriction of the DA (Hong et al., 2013).
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Genetic ablation of both MFN1 and MFN2 causes death in utero
during the mid-gestation period (Chen et al., 2003) whereas car-
diac-speciﬁc ablation of both Mitofusins in the embryo has been
shown to belethal at day E9.5–10.5 (Chen et al., 2011). Together,
these ﬁndings imply a role for the Mitofusins in cardiac develop-
ment. Conditional ablation of cardiomyocyte-speciﬁc MFN2 (α-
MHC-Cre) in the adult murine heart causes mitochondria to be-
come pleiomorphic and slightly enlarged while the hearts dis-
played modest LV hypertrophy and a mild deterioration in LV
systolic function (Y. Chen et al., 2012; Papanicolaou et al., 2011). In
contrast, the genetic ablation of cardiac-speciﬁc MFN1 in the adult
heart did not appear to induce a marked cardiac phenotype (Pa-
panicolaou, Nogh, et al., 2012). As expected, the combined ablation
of both cardiac MFN1 and MFN2 in the adult murine heart resulted
in mitochondrial fragmentation with disordered cristae morphol-
ogy and induced a lethal cardiomyopathy after several weeks
(Papanicolaou, Kikuchi, et al., 2012; Chen et al., 2011).
4.3. OPA1 and the adult heart
The role for OPA1 in the adult heart has been investigated in
mice partially deﬁcient in this protein, given that the complete
ablation of OPA1 causes in utero death (Davies et al., 2007). The
transgenic OPA1 þ/ mice has a 50% reduction in myocardial
OPA1 and displays enlarged mitochondria with disrupted cristae
and altered mitochondrial organisation. These mice exhibit only a
mild cardiac phenotype at 3 and 6 months but start to develop
heart failure at 12 months. The mutation in OPA1 causes cardiac
dysfunction with a reduced cardiac output, blunted inotropic re-
serve and impaired pressure–volume loops (L. Chen et al., 2012b).
4.4. Drp1 and the adult heart
Genetic ablation of Drp1 is embryonically lethal at day E12.5
(Manczak et al., 2012). Cardiac-speciﬁc ablation of Drp1 in the
adult heart has been shown to produce a cardiomyopathy due to
mitochondrial dysfunction arising from an impaired mitophagic
response (Ikeda et al., 2015), underscoring the importance of
Drp1-mediated ﬁssion in maintaining a healthy mitochondrial
network. These ﬁndings will limit inhibition of Drp1 as a ther-
apeutic approach to the acute setting, given that chronic Drp1
inhibition is likely to be detrimental for cardiac function.5. Mitochondrial fusion and ﬁssion proteins in cardiovascular
disease
5.1. Vascular smooth muscle cell proliferation
Vascular smooth muscle cell (VSMC) proliferation and hyper-
plasia have been identiﬁed to be hallmark features in a variety ofTabel 1
Potential therapeutic approaches to modulate changes in mitochondrial morphology du
Clinical condition Experimental observation
Acute ischaemia/reperfusion (heart,
kidney and brain)
Mitochondria undergo ﬁssion in response to isc
Heart failure MFN1 or MFN2 ablation induces a cardiomyopa
Heart failure is associated with reduction in my
expression
Left ventricular hypertrophy MFN2 or OPA1 ablation induces left ventricle h
Pulmonary arterial hypertension Vasculoproliferation requires Drp1-mediated ﬁs
terial hypertension associated with down-regulcardiovascular diseases including coronary atherosclerosis, hy-
pertension and pulmonary arterial hypertension (PAH). The ex-
istence of VSMC proliferation and hyperplasia causes failure of
coronary artery bypass vein grafts and restenosis following per-
cutaneous coronary intervention. As such, novel therapeutic tar-
gets are required to inhibit VSMC proliferation in these settings. In
this regard, the mitochondrial fusion and ﬁssion proteins may
provide novel targets for preventing this pathological process.
5.1.1. MFN2 and VSMC proliferation
MFN2 was originally identiﬁed as a novel hyperplasia sup-
pressor gene (HSG), capable of inhibiting VSMC proliferation in a
variety of vasculo-proliferative conditions (Chen et al., 2004). The
overexpression of MFN2 was shown to inhibit VSMC proliferation
in an experimental animal model of angioplasty balloon-induced
neointimal injury, oxidised LDL and subsequent atheroma forma-
tion and carotid artery restenosis. The anti-proliferative effect of
MFN2 was found to be due to PKA-induced phosphorylation of
MFN2 at Ser442 (Zhou et al., 2010). Down-regulation of MFN2 was
shown to enhance VSMC proliferation, a ﬁnding which was ac-
companied by an increase in fatty acid oxidation and decrease in
glucose oxidation. These results suggest that changes in mi-
tochondrial morphology and bioenergetics may underlie the hy-
perproliferative features of the VSMC in this setting.
5.1.2. Drp1 and VSMC proliferation
The role of the mitochondrial ﬁssion protein Drp1 in pro-
liferation of VSMCs has been studied by Chalmers et al. (2012) who
found that in native non-proliferative quiescent VSMCs mi-
tochondria were fairly static mainly ovoid in shape whereas during
proliferation, the mitochondria became more mobile and dis-
played varying shapes. Following angiotensin II (Ang II) stimula-
tion, activated Drp1 interacted with PKC-δ and then activated
MEK1/2–ERK1/2 signalling cascade and MMP2 (Lim et al., 2015).
Treatment of VSMCs with the Drp1 inhibitor,mdivi-1, impaired the
proliferative response, suggesting that mitochondrial ﬁssion may
be required for VSMC proliferation (Lim et al., 2015). The re-
quirement for mitochondrial ﬁssion in VSMC proliferation has
been recently explored in the setting of PAH.
5.2. Pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is deﬁned as a condition
where the pulmonary arteries become obstructed, resulting in
right ventricular hypertrophy and heart failure. In this regard, re-
cent experimental data has implicated the mitochondrial fusion
and ﬁssion proteins as potential novel therapeutic targets for
treating PAH (see Table 1).
5.2.1. Mitochondrial fusion proteins and PAH
Similarly, both MFN2 and PGC-1α were down-regulated in
pulmonary arterial smooth muscle cells (PASMC) in two differentring pathophysiological cardiac conditions.
Potential therapeutic approach
haemia/reperfusion Inhibit mitochondrial ﬁssion using mdiv-1, dynasore, P110
to protect against acute ischaemia/reperfusion injury
thy Activate MFN1, MFN2 or OPA1 to prevent heart failure
ocardial OPA1
ypertrophy Activate MFN2 or OPA1 to prevent left ventricular
hypertrophy
sion. Pulmonary ar-
ation of MFN2
Inhibit mitochondrial ﬁssion using mdiv-1, dynasore, P110
Activates MFN2
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MFN2 reversed this phenotype. Together, these ﬁndings implicate
the mitochondrial-shaping proteins as novel therapeutic targets
for PAH (Marsboom et al., 2012). Although preventing PAH by
using mdivi-1 is beneﬁcial short-term, the feasibility remains to be
determined as chronic inhibition of mitochondrial ﬁssion may be
detrimental.
5.2.2. Mitochondrial ﬁssion proteins and PAH
Hyperproliferation of the PASMC is an essential part of the
pathophysiology underlying PAH. It has been demonstrated that
the ability of mitochondria to divide is central to equal re-dis-
tribution of mitochondria during cell proliferation. The fragmen-
tation of the mitochondria was due to upregulation of Drp1 and
downregulation of MFN2, coupled with Cyclin B1/CDK1 phos-
phorylation of Drp1 at Ser616. Interestingly, treatment with the
small molecule Drp1 inhibitor, mdivi-1, was shown to prevent the
progression of PAH in three different experimental models of PAH
(Marsboom et al., 2012).
5.3. Heart failure
The development of heart failure has been documented to in-
volve deﬁciencies in either the mitochondrial fusion or ﬁssion
proteins (see Table 1). Nevertheless, whether these changes in
mitochondrial-shaping proteins directly cause heart failure or
merely constitute a consequence of the alteration of mitochondrial
biogenesis remains to be determined (Garnier et al., 2005; Ven-
tura-Clapier et al., 2011).
5.3.1. Mitochondrial fusion proteins and heart failure
Deﬁciencies in cardiac MFN1 and MFN2 have been shown to
result in a mild cardiomyopathy (Y. Chen et al., 2012; Papanicolaou
et al., 2011). In another study, the genetic ablation (Mlc2v-Cre) of
MFN2 in the adult murine heart produced no obvious cardiac
phenotype in mice up to 4 months of age (Zhao et al., 2012). It was
only at 17 months of age that the MFN2-KO mice displayed in-
creased sensitivity to acute IRI, and developed late-onset LV dys-
function (Zhao et al., 2012). These ﬁndings were associated with a
major metabolic disturbance with impaired autophagy, defective
lipid metabolism, and decreased mitochondrial respiration (pri-
marily at complex III) (Zhao et al., 2012). The explanation for the
observed differences in effects of MFN2 ablation in the adult heart
is not clear. Whether the difference in response to MFN2 ablation
can be attributed to the use of different cardiac-speciﬁc promoters
is not known.
Using a post-MI rat heart failure model and human dilated and
ischaemic cardiomyopathy tissue samples, the fragmentation of
the mitochondria due to decreased myocardial levels of OPA1 was
demonstrated (Chen et al., 2009). Partial deﬁciency in OPA1 also
reduced mitochondrial DNA copy number and decreased expres-
sion of nuclear antioxidant genes at 3–4 months (L. Chen et al.,
2012). Nevertheless, baseline cardiac function was found to be
normal in these OPA1-deﬁcient mice, although cardiomyopathy
associated with mitochondrial fragmentation and impaired mi-
tochondrial function developed at 12 months of age (L. Chen et al.,
2012). The reason for the decline of OPA1 levels in heart failure
requires further investigation. Similarly during initial compensa-
tory cardiac hypertrophy, an increase in OPA1 and decrease in
Drp1 occur in concert with decreased Parkin and Sirt1/AMPK-PGC-
1α signalling, signifying a compromised mitochondrial remodel-
ling system (Tang et al., 2014).
The silencing of MARF (mitochondrial assembly regulatory
factor – ortholog of mammalian, Mitofusin) and OPA1 in the
Drosophila ﬂy heart tube causes dilated cardiomyopathy, which
could be rescued by over-expressing either of the humanMitofusins (MFN1 or MFN2) or superoxide dismutase 1, implicat-
ing impaired mitochondrial fusion and oxidative stress in the pa-
thogenesis of the heart failure (Dorn, 2011). Fragmentation of the
mitochondria and impairment of mitochondrial respiration re-
sulting from conditional cardiac-speciﬁc combined ablation of
MFN1 and MFN2 in the adult murine heart have been reported to
result in a severe lethal dilated cardiomyopathy after 6–8 weeks,
implicating a role for the Mitofusins in maintaining normal mi-
tochondrial function in the adult heart (Chen et al., 2011). A de-
crease in MFN2, an increase in Fis1, and no change in OPA1 ex-
pression were also detected in rat hearts 12–18 weeks after
myocardial infarction (Javadov et al., 2011). The ablation of MFN2
in hearts also leads to impaired Parkin-mediated mitophagy
causing an accumulation of damaged ROS-producing organelles
and progressive heart failure. An optimally suppressed mi-
tochondrial ROS prevented mitochondrial depolarisation, re-
spiratory impairment, and structural degeneration in MFN2-null
hearts. Super-suppressed mitochondrial ROS which was associated
with impaired secondary autophagic pathways, however, failed to
improve mitochondrial health, suggesting the importance of mi-
tochondrial ROS alongside mitochondrial dynamics in mediating
mitophagy and minimise cardiac failure (Song et al., 2014). Parkin
deﬁciency and resulting mitophagic disruption causes an accu-
mulation of enlarged hollow donut mitochondria with dilated
cardiomyopathy (Bhandari et al., 2014). Suppressing mitochondrial
fusion completely prevented the cardiomyopathy and corrected
mitochondrial dysfunction, albeit mitochondrial dysmorphology
was not normalised, demonstrating the link among improper
mitochondrial fusion, defective mitophagy and organ dysfunction
(Bhandari et al., 2014).
5.3.2. Mitochondrial ﬁssion proteins and heart failure
Ashraﬁan et al. (2010) have described a novel mutation in the
Drp1 gene (C452F) which gives rise to an autosomal dominant
form of dilated cardiomyopathy in the python mouse. The
homozygous mutation is embryonically lethal but the hetero-
zygous form survived until adulthood and developed a severe di-
lated cardiomyopathy after 11 weeks, a ﬁnding which was asso-
ciated with reduced content of mitochondrial respiratory enzymes
and ATP (Ashraﬁan et al., 2010). While increased mitochondrial
ﬁssion due to an up-regulation of Drp1 has been previously linked
to heart failure, a decrease in SUMO attachment to Drp1 has been
detected in SENP5-Tg hearts. The mitochondria of the SENP5-Tg
hearts were signiﬁcantly larger during the early developmental
stage which would account for the pathological change observed
(Kim et al., 2015). Aberrant mitophagy and elevated mitochondrial
oxidative stress contribute to abnormal activation of MMP-9,
leading to degradation of the gap junction protein connexin-43
(Cx-43) in the ventricular myocardium (Jansen et al., 2012; Giv-
vimani et al., 2010). Reduced Cx-43 levels were associated with
increased ﬁbrosis and ventricular dysfunction in heart failure
(Jansen et al., 2012). Treatment with mdivi-1 normalised the de-
creased ratio of MFN2 to Drp1 (Gharanei et al., 2013) as well as the
expression levels of MMP-9 and Cx-43, thus showing an improved
cardiac function (Sharp et al., 2014; Givvimani et al., 2010; Givvi-
mani et al., 2012).
5.4. Acute ischaemia–reperfusion injury
Acute IRI is derived from the opening of the MPTP at the onset
of reperfusion following a sustained period of ischaemia. The
susceptibility of the heart to acute IRI and its recovery is critically
dependent on the function of its mitochondria. Therefore, the
preservation of mitochondrial function and the prevention of
MPTP opening during acute IRI are important therapeutic strate-
gies for cardioprotection. Recent experimental data suggests that
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heart may impact on the susceptibility to acute IRI providing novel
therapeutic targets for cardioprotection (see Table 1).
5.4.1. Mitochondrial ﬁssion proteins and IRI
In response to acute IRI, fragmentation of the mitochondria by
Drp1 was detected (Ong et al., 2010; Din et al., 2013). The inhibi-
tion of Drp1 in the HL-1 cardiac cell line using genetic or phar-
macological approaches prevented the opening of the MPTP and
reduced cell death. In the murine heart, pharmacological inhibi-
tion of Drp1 reduced cell death in isolated cardiomyocytes sub-
jected to simulated IRI and reduced MI size in the adult murine
heart subjected to in vivo acute IRI. Pre-treatment with mdivi-1 in
the brain signiﬁcantly reduced oxidative stress, upregulated Bcl-2
expression, and downregulated Drp1, BAX, and cytc expression
(Wang et al., 2014; Zhao et al., 2014). In the heart, mdivi-1 reduced
mitochondrial reactive oxygen species, improved LV developed
pressure, and lowered LV end diastolic pressure following IR, an
effect which was also mirrored using the calcineurin inhibitor,
FK506 (Sharp et al., 2014). Other studies also provided evidence
that inhibition of Drp1-mediated mitochondrial ﬁssion by various
upstream pathways protected the heart, e.g. over-expression of
Pim1 kinase (Din et al., 2013) and usage of the non-speciﬁc dy-
namin inhibitor, Dynasore (Gao et al., 2013). Drp1 inhibition con-
fers cardioprotection by reducing mitochondrial metabolism dur-
ing I/R (Zepeda et al., 2014). The protective effects of inhibiting
mitochondrial ﬁssion have also been detected in the kidney and
the brain, suggesting that therapeutic targeting mitochondrial
ﬁssion may be beneﬁcial in other organs (N. Zhang et al., 2013).
Most recently, a speciﬁc peptide inhibitor of Drp1, named P110, has
been used to demonstrate that inhibiting mitochondrial ﬁssion at
reperfusion can reduce myocardial infarct size and prevent ad-
verse left ventricular remodelling post-MI in the adult rat heart
(Disatnik et al., 2013) as well as in the brain (Guo et al., 2014).
Futhermore, the discovery of other components of the mitochon-
drial ﬁssion machinery such as Mff and MiD49/51 raises the pos-
sibility of inhibiting these other proteins to mediate cardiopro-
tection (Long et al., 2013). However, this therapeutic strategy will
only be useful in protecting the heart against acute episodes of IRI
as this can be achieved by transient pharmacological inhibition of
mitochondrial ﬁssion. The chronic inhibition of mitochondrial
ﬁssion would be detrimental to the heart and other organs as this
process is critical to maintaining a healthy mitochondrial network
(Ikeda et al., 2015). The opening of the MPTP following ischaemia
has also been postulated to be caused by hexokinase II (HKII)
dissociation from the mitochondrial contact sites at the OMM and
IMM. Nevertheless, the interaction between HKII and Drp1 in
maintenance of the contact sites remains to be determined (Pas-
dois et al., 2013; Halestrap et al., 2015). The SUMO-2/3-speciﬁc
protease SENP3 is also found to be degraded during ischaemia, via
a pathway involving the unfolded protein response (UPR) kinase
PERK and the lysosomal enzyme cathepsin B. Ischaemia-induced
cell death is suppressed as depletion of SENP3 prolongs Drp1
SUMOylation. Upon reoxygenation, recovery of levels of SENP3
allows deSUMOylation of Drp1, which facilitates Drp1 localisation
at mitochondria and promotes fragmentation and cytc release
(Guo et al., 2013).
5.4.2. Mitochondrial fusion proteins and IRI
The role of the mitochondrial fusion proteins (MFN1, MFN2 and
OPA1) as targets for cardioprotection has been established, al-
though the pleiotropic non-fusion effects need to be taken into
account. Our laboratory has demonstrated that over-expressing
MFN1 or MFN2 in the HL-1 cardiac cell line prevented the opening
of the MPTP and reduced cell death following simulated IRI (Ong
et al., 2010). Consistent with a potential protective role of theMFN2, it was demonstrated in neonatal cardiomyocytes that the
genetic ablation of MFN2 increased MPTP opening susceptibility
and worsened cell death; however, contrasting ﬁndings were
found in MFN2-deﬁcient adult cardiomyocytes with protection
against cellular injury (Papanicolaou et al., 2011).
Although partial ablation of OPA1did not signiﬁcantly alter
cardiac function, the size of the mitochondria was increased with
the formation of clusters of fused mitochondria and altered cristae.
Interestingly, MPTP opening to calcium accumulation was less
sensitive (Piquereau et al., 2012). The studies conducted so far
have focused on the effects of genetically ablating the mitochon-
drial fusion proteins yet there is still a gap in terms of determining
sensitivity to acute IRI by over-expressing the mitochondrial fusion
proteins in the adult heart. In summary, the role of the mi-
tochondrial fusion proteins in the adult heart in terms of sus-
ceptibility to acute IRI is quite complex. However, the develop-
ment of small molecule inhibitors of MFN1 and MFN2 may provide
a novel therapeutic strategy for cardioprotection.
Up-regulation of Hand1, a basic helix–loop–helix transcription
factor highly expressed in the embryonic heart, has been de-
monstrated to be protective against myocardial ischaemia, forming
part of a novel regulatory pathway linking cardiac oxygen levels
with oxygen consumption (Breckenridge et al., 2013). During ATP-
depleted ischaemia in renal proximal tubular cells, knockdown of
OMA1 suppressed OPA1 proteolysis, mitochondrial fragmentation,
cytc release, and consequent apoptosis (Xiao et al., 2014). The pro-
survival kinase, Akt as well as its pharmacological activator, EPO
has also been postulated to confer cardioprotection by means of
elongating the mitochondria via modulation of MFN1 (Ong et al.,
2014).
5.5. Left ventricular hypertrophy
Hypertrophy of the left ventricle can be classiﬁed into either
physiological (in response to exercise) or pathological (congenital
or acquired – most often a detrimental response to an increase
load). LV hypertrophy can lead to an increased risk of arrhythmias,
regions of ischaemia and heart failure (Frey and Olson, 2003; Frey
et al., 2004). As such novel therapeutic agents are required to
prevent the progression of left ventricular hypertrophy (LVH) and
reduce the onset of heart failure. Samples of RV and LV obtained
from neonatal calves subjected to 2 weeks of hypobaric hypoxia
showed no differences between the ventricles in terms of mi-
tochondrial protein expression levels and mitochondrial activity
(Bruns et al., 2015). Mitochondrial DNA was unchanged, as was
mitochondrial content and mitochondrial dynamics. Activity of
individual respiratory chain complexes was reduced (complex I) or
unchanged (complex V). Key enzymes in the glycolysis pathway
were upregulated in both ventricles, alongside upregulation of
hypoxia inducible factor 1-α protein (Bruns et al., 2015). Whether
these ﬁndings reﬂect a difference between developmental stages
(neonatal vs adult), experimental models of inducing hypertrophy,
or species differences, warrant further investigation.
5.5.1. Mitochondrial fusion proteins and LV hypertrophy
MFN2 (formerly known as hyperplasia suppressor gene or HSG)
has been demonstrated to inhibit proliferation of VSMC by sup-
pressing MEK1/2–Erk1/2, a pathway which is up-regulated in LVH
(Fang et al., 2007). Using different experimental models of LVH
(phenylephrine induced LVH in neonatal rat cardiomyocytes,
spontaneously hypertensive rats, β2-adrenergic transgenic mice,
and pressure overload LVH by transverse aortic constriction), Fang
et al. (2007) demonstrated that MFN2 expression was down-
regulated and Erk1/2 up-regulated. Similarly, angiotensin-II
treatment in neonatal rat cardiomyocytes decreased MFN2 ex-
pression while elevating Akt levels. Over-expressing MFN2
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and the intact rat heart (Yu et al., 2011). It is noteworthy to point
that the reduction in MFN2 levels should be compared against
total mitochondrial number as LVH can result in reduction of mi-
tochondrial mass. The effect of MFN2 in cardiac hypertrophy was
further elucidated using mice with cardiac-speciﬁc MFN2 knock-
out, where a loss of tethering to the ER may cause impaired Ca2þ
signalling or enhanced ROS production (Chen and Dorn, 2013;
Papanicolaou et al., 2011).
Partial deﬁciency in OPA1 also increases susceptibility to LVH
and cardiac dysfunction induced by total aortic constriction (TAC)
(Piquereau et al., 2012). Nevertheless, whether OPA1 over-ex-
pression could similarly reverse this phenotype remains to be
investigated.
5.5.2. Mitochondrial ﬁssion proteins and LV hypertrophy
Compared to the fusion proteins MFN2 and OPA1, the ﬁssion
protein Drp1 was shown to be up-regulated in a cell model of phe-
nylephrine-induced cardiomyocyte hypertrophy, suggesting a shift to
mitochondrial fragmentation and enhanced levels of mitophagy may
be associated with the development of LVH (Javadov et al., 2011;
Givvimani et al., 2012). Inhibiting mitochondrial fragmentation with
the Drp1 inhibitor mdivi-1 enhanced the maintenance of the mi-
tochondrial population, a release of pro-angiogenic factors (CD31 and
VEGF) and a reduced collagen deposition which prevented the pro-
gression of LVH and development to heart failure induced by pres-
sure overload TAC (Givvimani et al., 2012). These ﬁndings were also
mirrored in a quantitative phosphoproteomics study by Chang et al.
(2013) using myocardial samples at different time points following
transverse aortic banding (TAB). Phosphorylation of DRP1 S622 and
subsequent mitochondrial translocation were detected in TAB-trea-
ted mouse hearts and phenylephrine (PE)-treated rat neonatal car-
diomyocytes (Chang et al., 2013). The hypertrophic response and
oxygen consumption were reduced in response to treatment with
mdivi-1 (Chang et al., 2013). These ﬁndings suggest a potential
therapeutic strategy in acute inhibition of mitochondrial ﬁssion
proteins to salvage LV hypertrophy (see Table 1).
5.6. Stem cell differentiation into cardiomyocytes
The process of differentiation from cardiac stem cells to adult
cardiomyocytes required changes in mitochondrial function and
architecture to accommodate for the increased metabolic demands
of the differentiated beating cardiomyocyte (reviewed in Rehman
(2010)). Furthermore, a switch from anaerobic glycolysis to oxi-
dative phosphorylation is crucial for the differentiation process
(Chung et al., 2007). The change in mitochondrial metabolism has
been reported to be associated with a change in mitochondrial
morphology from a fragmented state (lacking cristae) in the ESC,
to an elongated state (with well-developed cristae), closely aligned
with the myoﬁbrils of the differentiated contractile cardiomyocyte
(Chung et al., 2007). The alteration in expression level of Drp1 and
MFN2 mediates this change in mitochondrial morphology (Chung
et al., 2007). A recent experimental study has shown that the
presence of OPA1 and MFN2 is required in the development of the
heart, with developmental arrest occurring at E13.5 (Kasahara
et al., 2013). Differentiation from ESC to cardiomyocytes was as-
sociated with an increased expression of MFN2 and OPA1. Al-
though knockout of MFN2 and OPA1 failed to affect mitochondrial
biogenesis, the mitochondrial network failed to elongate and the
cells were no longer able to differentiate into beating cardiomyo-
cytes. The ablation of these pro-fusion proteins affected calcium
signalling activity which subsequently impaired calcineurin ac-
tivity and Notch signalling (Kasahara et al., 2013). Elevation of
Drp1 expression and dephosphorylation of Drp1 at Ser637 also
promoted differentiation of C2C12 myoblasts induced by serumstarvation. Perturbation of mitochondrial fragmentation by mdivi-
1 or Drp1K38A hinders myogenic differentiation (Kim et al., 2013).
Therefore, modulation of mitochondrial morphology may exert an
inﬂuence on manipulation of differentiation of cardiac stem cells.
More recently, expression of prohibitin 2 (PHB2), a pleiotrophic
factor mainly localised in mitochondria, mediates homoeostasis
and differentiation of ES cells. The level of PHB2 is elevated in
undifferentiated mouse ES cells, while the expression was de-
creased during the differentiation of ES cells. The change in ex-
pression pattern of PHBs causes aberrations of mitochondrial
functions by modulating the processing of OPA1, yet the effects on
OPA1 does not seem to affect differentiation of ES cells (Kowno
et al., 2014).6. Limitations and future therapeutic potential of targeting
the mitochondrial fusion and ﬁssion proteins
The targeting of mitochondrial morphology hails a new cor-
nerstone in designing new therapies for combating cardiovascular
disease (see Table 1 for summary). In general the acute inhibition
of mitochondrial ﬁssion and the acute activation of MFN2 or OPA1
may provide a novel therapeutic strategy in a number of cardio-
vascular diseases. However, the current potential of modulation
mitochondrial morphology as a therapeutic strategy is limited to
acute therapeutic manipulation as the chronic modulation of mi-
tochondrial morphology whether that be inhibition of ﬁssion or
activation of fusion would be deleterious in the long term.7. Summary and conclusions
Mitochondria are now regarded as highly dynamic organelles
with multiple roles in cell death and survival. Emerging data
suggests that the mitochondrial fusion and ﬁssion proteins may
provide novel therapeutic targets for treating a variety of cardio-
vascular diseases including acute IRI, heart failure, left ventricular
hypertrophy, and pulmonary arterial hypertension (see Table 1).
However, further work is needed to better understand the pleio-
tropic roles the mitochondrial shaping proteins may play in the
cardiovascular system (see Fig. 1), as this may impact on the ap-
plication of therapeutic strategies which target mitochondrial
morphology.Funding
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